8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 23, 2009 (November 18, 2009)

AMSURG CORP.

(Exact Name of Registrant as Specified in Charter)

Tennessee	000-22217	62-1493316
(State or Other Jurisdiction of	(Commission	(I.R.S. Employer
Incorporation)	File Number)	Identification No.)

20 Burton Hills Boulevard
Nashville, Tennessee	37215
(Address of Principal Executive Offices)	(Zip Code)

(615) 665-1283
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     On November 18, 2009, the board of directors of AmSurg Corp. (the “Company”) appointed John W. Popp, Jr., M.D. to serve as a Class III director of the Company. The board of directors did not appoint Dr. Popp to serve as a member of any of the committees of the board.

     Effective November 18, 2009, the Company approved a grant of restricted common stock to Dr. Popp pursuant to the Company’s 2006 Stock Incentive Plan, as amended, having a fair market value on the date of grant equal to $12,500. The shares of restricted common stock shall vest in equal one-third installments on the date of grant and each of the first and second anniversaries of the date of grant, provided that Dr. Popp is still a director of the Company on such dates. Until the earlier of (i) five years from the date of grant and (ii) the date on which Dr. Popp ceases to serve as a director of the Company, he may not sell or transfer the restricted stock other than by will or by the laws of descent and distribution. Upon the termination of Dr. Popp’s service as a director for any reason other than death or disability, any unvested shares of restricted stock will be forfeited. Upon the termination of Dr. Popp’s service as a director due to death or disability, any unvested shares of restricted stock will vest immediately.

     Dr. Popp is not a party to any arrangement or understanding with any person pursuant to which Dr. Popp was appointed as a director, nor is Dr. Popp a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     A copy of the press release announcing Dr. Popp’s appointment to the board of directors is included herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

     (d) Exhibits

99.1 Press Release

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMSURG CORP.
By:	/s/ Claire M. Gulmi
	Claire M. Gulmi
	Executive Vice President, Chief Financial Officer and Secretary (Principal Financial and Duly Authorized Officer)

Date: November 23, 2009

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE	Contact:	Claire M. Gulmi
		Executive Vice President and
		Chief Financial Officer
		(615) 665-1283

AMSURG NAMES JOHN W. POPP, JR., M.D. TO BOARD OF DIRECTORS

NASHVILLE, Tenn. — (November 23, 2009) — AmSurg Corp. (NASDAQ: AMSG), today announced the appointment of John W. Popp, Jr., M.D. to its Board of Directors. Dr. Popp is Clinical Professor of Medicine at the University of South Carolina School of Medicine and a Medical Director for Centocor, Inc., a unit of Johnson and Johnson, which provides innovative biomedicines for debilitating immune disorders. Dr. Popp is a board-certified internist and gastroenterologist. Since 1998, he has served on the Board of Trustees for the American College of Gastroenterology and is a past President of the College. Dr. Popp is a cum laude graduate of both Yale Medical School and Vanderbilt University.

     Christopher A. Holden, President and Chief Executive Officer of AmSurg, remarked, “We are very pleased to name such an eminent gastroenterologist as Dr. Popp to our Board of Directors. Throughout his career, Dr. Popp has distinguished himself through his practice of medicine and through his extensive research and publications. He brings a unique perspective as a physician to our Board, and his appointment is a reflection of AmSurg’s focus on continually enhancing the value proposition we provide our physician partners and our ability to be their strategic partner of choice. With Dr. Popp’s experience and leadership capabilities, we are confident he will contribute to our achieving these goals and to the long-term growth of AmSurg.”

     AmSurg Corp. acquires, develops and operates ambulatory surgery centers in partnership with physician practice groups throughout the United States. At September 30, 2009, AmSurg owned a majority interest in 194 continuing centers in operation and had two centers under development.

-END-